Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease

BACKGROUND: Respiratory syncytial virus (RSV) is a viral pathogen that causes annual epidemics of lower respiratory tract infection with substantial morbidity and mortality in young children, especially those with congenital heart disease (CHD). Palivizumab is the only immunoprophylaxis therapy appr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Saudi Med
Autors principals: Mohammed, Mohammed Hassan A., Agouba, Rihab, Obaidy, Islam El, Alhabshan, Fahad, Abu-Sulaiman, Riyadh
Format: Artigo
Idioma:Inglês
Publicat: King Faisal Specialist Hospital and Research Centre 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7868616/
https://ncbi.nlm.nih.gov/pubmed/33550912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5144/0256-4947.2021.31
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars